Cs Diagnostics Corp. (CSDX) — SEC Filings
Cs Diagnostics Corp. (CSDX) — 4 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 2 10-Q, 2 8-K.
View Cs Diagnostics Corp. on SEC EDGAR
Overview
Cs Diagnostics Corp. (CSDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: CS DIAGNOSTICS CORP. (CSDX) reported a net income of $32,081 for the nine months ended September 30, 2025, a significant increase from $13,448 in the prior-year period. This improvement was primarily driven by a substantial reduction in total operating expenses, which decreased to $62,119 from $92,9
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 1 bearish, 2 neutral, 1 mixed. The dominant filing sentiment for Cs Diagnostics Corp. is neutral.
Filing Type Overview
Cs Diagnostics Corp. (CSDX) has filed 2 10-Q, 2 8-K with the SEC between Oct 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (4)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 13, 2025 | 10-Q | CSDX Net Income Jumps on Cost Cuts, Revenue Dips Amid Cash Crunch | high |
| Oct 31, 2025 | 8-K | CS Diagnostics Corp. Files 8-K | low |
| Oct 9, 2025 | 10-Q | CSDX Net Income Jumps 150% on Cost Cuts, Revenue Dips 28% | high |
| Oct 3, 2024 | 8-K | CS Diagnostics Corp. Relocates Principal Executive Offices | low |
Risk Profile
Risk Assessment: Of CSDX's 4 recent filings, 2 were flagged as high-risk, 0 as medium-risk, and 2 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $94,200 |
| Net Income | $32,081 |
| EPS | $0.00 |
| Debt-to-Equity | 0.00 |
| Cash Position | $13 |
| Operating Margin | -0.19% |
| Total Assets | $499,431,013 |
| Total Debt | $1,609 |
Industry Context
CS Diagnostics Corp. operates in the medical technology sector, focusing on diagnostic and therapeutic products. The industry is characterized by innovation, regulatory oversight, and the need for significant R&D investment. Companies often collaborate with research institutions and healthcare providers to bring new technologies to market.
Top Tags
Going Concern (2) · Small Cap (2) · OTCQB (2) · Diagnostics (1) · Medical Technology (1) · Regulatory Services (1) · Liquidity Crisis (1) · 8-K (1) · corporate-filing (1) · company-history (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $32,081 | Increased from $13,448 in prior year, driven by cost reductions. |
| Total Revenue | $94,200 | Decreased by 11% from $106,381 in prior year, due to reduced diagnostic activity. |
| Total Operating Expenses | $62,119 | Decreased significantly from $92,933, primarily due to lower professional fees. |
| Cash and Cash Equivalents | $13 | Critically low, down from $501 at year-end 2024, indicating severe liquidity issues. |
| Net Cash Used in Operating Activities | $(528) | Negative cash flow from operations for the nine months ended September 30, 2025. |
| Intangible Assets | $499.4M | Represents the vast majority of total assets, raising questions about asset liquidity and valuation. |
| Accumulated Deficit | $(4,735,847) | Indicates historical losses and ongoing financial challenges. |
| Revenue Decrease | 11% | Percentage decline in total revenues for the nine months ended September 30, 2025, compared to 2024. |
| Common Stock Shares Outstanding | 137,340,200 | As of September 30, 2025. |
| Total Liabilities | $1,609 | As of September 30, 2025, a slight increase from $1,428 at December 31, 2024. |
| Net Income (6 months) | $32,263 | Increased from $12,912 in prior year, a 150% rise. |
| Revenue (6 months) | $71,150 | Decreased by 28% from $98,417 in prior year. |
| Operating Expenses (6 months) | $38,887 | Decreased significantly from $85,505 in prior year. |
| Cash | $196 | Extremely low, down from $501 at year-end 2024. |
| Net Cash Provided by Financing Activities | $499.4M | Reflects significant equity infusions to cover investing activities. |
Frequently Asked Questions
What are the latest SEC filings for Cs Diagnostics Corp. (CSDX)?
Cs Diagnostics Corp. has 4 recent SEC filings from Oct 2024 to Nov 2025, including 2 10-Q, 2 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CSDX filings?
Across 4 filings, the sentiment breakdown is: 1 bearish, 2 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cs Diagnostics Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cs Diagnostics Corp. (CSDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cs Diagnostics Corp.?
Key financial highlights from Cs Diagnostics Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CSDX?
The investment thesis for CSDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cs Diagnostics Corp.?
Executive information for Cs Diagnostics Corp. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Cs Diagnostics Corp. stock?
Of CSDX's 4 assessed filings, 2 were flagged high-risk, 0 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Cs Diagnostics Corp.?
Forward guidance and predictions for Cs Diagnostics Corp. are extracted from SEC filings as they are enriched.